What is FRUZAQLA® (fruquintinib)?

FRUZAQLA is a non-chemotherapy kinase inhibitor

Treatments are needed in metastatic colorectal cancer (mCRC) to improve outcomes and preserve quality of life. FRUZAQLA may be able to help. FRUZAQLA is a kinase inhibitor of vascular endothelial growth factor receptors (VEGFRs) for adult patients with previously treated mCRC, regardless of mutation status.1-4 

•    Approved in 2023 based on the FRESCO and FRESCO-2 clinical trials
•    Convenient, once-daily oral dosing4
•    An innovation in mCRC treatment4


Treatments that extend survival while preserving QoL are needed in metastatic colorectal cancer (mCRC)1-3

Colorectal cancer (CRC) can be deadly, with low survival rates for patients with metastatic disease3

About 70% of patients with CRC will experience metastatic disease.

of patients with CRC will experience metastatic disease, whether at diagnosis or over the course of treatment1

The 5-year relative survival rate is 14% for patients with distant mCRC.

5-year relative survival rate for patients with distant mCRC5

The incidence of mCRC in patients younger than 50 years of age, while relatively low, is increasing at a worrying pace5,6

Despite a majority of patients with mCRC being ≥65 years of age between 2010 and 2019, the greatest increase in mCRC was seen in younger patients6

Between 2010 and 2019, there was a 22.1% increase in patients 18 to 49 years of age, a 14.9% increase in patients 50 to 64 years of age, and a 21.6% increase in patients greater or equal to 65 years old.
Understanding the underlying causes and the treatment options for patients of all ages remains critical in oncology.

Selecting the right treatment at the right time is imperative for maximizing the benefit of therapy7-9

Progression in mCRC often leads to fewer patients reaching a third or fourth treatment or beyond, either due to disease progression or a transition to BSC

In real-world settings...

In real world settings, 25% to 30% of patients advance after 2 prior treatments. 10% to 15% of patients advance after 3 prior treatments.

Treatment of CRC can be intense and can negatively impact QoL

The symptomology of CRC and cytotoxic agent treatment-related side effects can substantially impact patients’ well-being10

  • Fatigue, insomnia, and/or psychological challenges can all affect emotional, social, physical, and functional status10
  • Management of adverse events, to maintain quality of life, is a key consideration with current options for previously treated metastatic colorectal cancer11

Therapies that consider the delicate balance of efficacy, tolerability, and quality of life are desperately needed1-3
 


Choose FRUZAQLA® (fruquintinib)⏤an FDA-approved, oral therapy with Quality of Life data in previously treated adults with mCRC4

Many US veterans remain at risk of developing colorectal cancer, see the veterans downloadable PDF to learn more


National Comprehensive Cancer Network® (NCCN®) recommends Fruquintinib (FRUZAQLA®) as a potential treatment option for patients with previously treated mCRC, regardless of mutation status12,13 

Fruquintinib (FRUZAQLA®) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan- based chemotherapy, an antiVEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.4

Potential treatment algorithms*†‡

Potential treatment algorithms include beginning patients on an initial therapy of FOLFOX + bevacizumba or FOLFIRINOX + bevacizumab. If no success with initial treatments, patients can move to subsequent treatments, including FRUZAQLA®.
*Other permutations and combinations are also recommended in NCCN guidelines. 
These examples are for BRAF and HER2 wild type, pMMR/MSS, and NTRK gene fusion negative disease, unless otherwise noted.12 
Please see NCCN Guideline for Colon or Rectal Cancer for full recommendations.
§If RAS mutant. 
If RAS wild type. 

FOLFIRI=leucovorin, fluorouracil, and irinotecan; FOLFIRINOX=leucovorin, fluorouracil, oxaliplatin, and irinotecan; FOLFOX=leucovorin, fluorouracil, and oxaliplatin; HER2=human epidermal growth factor receptor 2; MSS=microsatellite stable; pMMR=proficient mismatch repair.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.3.2025. © 2025 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.2.2025. © 2025 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. 

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

FRESCO-2 Efficacy Results

Learn about the efficacy results from FRESCO-2, a global, double-blind, placebo-controlled study with a heterogenous patient population.

FRESCO-2 Safety Profile

Explore the safety profile of FRUZAQLA from the FRESCO-2 clinical trial. 

Mechanism of
Action

Learn how FRUZAQLA​ works